TY - JOUR
T1 - Genetic medicine is accelerating in Japan
AU - Hayashi, Saori
AU - Kubo, Makoto
AU - Kaneshiro, Kazuhisa
AU - Kai, Masaya
AU - Yamada, Mai
AU - Morisaki, Takafumi
AU - Takao, Yuka
AU - Shimazaki, Akiko
AU - Shikada, Sawako
AU - Nakamura, Masafumi
N1 - Funding Information:
The authors thank Emiko Manabe, Shoko Sadatomi, Tamaki Nakagaki, Nobuhiro Torata, Midori Kojyo, and Emi Nagao for their technical assistance. We thank J. Ludovic Croxford, PhD, from Edanz Group (https://www.jp.edanz.com/ac) for editing a draft of this manuscript.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/7
Y1 - 2022/7
N2 - Background: In 2018, BRACAnalysis® was covered by medical insurance in Japan as a companion diagnostic test for the poly ADP-ribose polymerase inhibitor olaparib. In April 2020, eligibility for BRCA1/2 genetic testing was expanded to the diagnosis of hereditary breast and ovarian cancer syndrome, and medical management including prophylactic surgery and surveillance were covered by public insurance for BRCA1/2 mutation carriers who developed breast or ovarian cancer. The amount of BRCA1/2 genetic testing has been increasing recently, but the number of subjects and the impact of testing for patients’ outcomes remain unclear. Patients and methods: This study explored the potential number of patients who will be eligible for new insurance coverage for BRCA1/2 genetic testing. We analyzed 868 patients from 938 surgeries between January 2014 and September 2020 from our database. Results: Overall, 372 patients (43%) were eligible for new insurance coverage for BRCA1/2 genetic testing. The most common category was family history of breast or ovarian cancer within third-degree relatives. We found that 202 patients (23%) had family history of breast or ovarian cancer. In addition, the progression-free survival was significantly lower in triple-negative breast cancer patients aged 60 years or younger compared with the other patients (P = 0.0005). Conclusion: The genetic medicine for primary breast cancer patients with BRCA1/2 germline mutation is accelerating rapidly in Japan. Therefore, establishing a system for the genetic medicine would be urgent.
AB - Background: In 2018, BRACAnalysis® was covered by medical insurance in Japan as a companion diagnostic test for the poly ADP-ribose polymerase inhibitor olaparib. In April 2020, eligibility for BRCA1/2 genetic testing was expanded to the diagnosis of hereditary breast and ovarian cancer syndrome, and medical management including prophylactic surgery and surveillance were covered by public insurance for BRCA1/2 mutation carriers who developed breast or ovarian cancer. The amount of BRCA1/2 genetic testing has been increasing recently, but the number of subjects and the impact of testing for patients’ outcomes remain unclear. Patients and methods: This study explored the potential number of patients who will be eligible for new insurance coverage for BRCA1/2 genetic testing. We analyzed 868 patients from 938 surgeries between January 2014 and September 2020 from our database. Results: Overall, 372 patients (43%) were eligible for new insurance coverage for BRCA1/2 genetic testing. The most common category was family history of breast or ovarian cancer within third-degree relatives. We found that 202 patients (23%) had family history of breast or ovarian cancer. In addition, the progression-free survival was significantly lower in triple-negative breast cancer patients aged 60 years or younger compared with the other patients (P = 0.0005). Conclusion: The genetic medicine for primary breast cancer patients with BRCA1/2 germline mutation is accelerating rapidly in Japan. Therefore, establishing a system for the genetic medicine would be urgent.
UR - http://www.scopus.com/inward/record.url?scp=85124960851&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124960851&partnerID=8YFLogxK
U2 - 10.1007/s12282-022-01342-4
DO - 10.1007/s12282-022-01342-4
M3 - Article
C2 - 35191009
AN - SCOPUS:85124960851
SN - 1340-6868
VL - 29
SP - 659
EP - 665
JO - Breast Cancer
JF - Breast Cancer
IS - 4
ER -